MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding MoonLake Immunotherapeutics changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 111 | 1 | 109 | −1 |
| Shares | 60.8M | 392.0K | 62.3M | +1.84M (+3.0%) |
| Value | $2.67B | $17.2M | $3.14B | +$482.4M (+18.2%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 931,480 | $47.0M | 1.64% |
| Hood River Capital Management LLC | 646,662 | $32.6M | 0.53% |
| BlackRock, Inc. | 400,785 | $20.2M | 0.00% |
| Saturn V Capital Management LLC | 298,974 | $15.1M | 5.39% |
| Ameriprise Financial Inc | 159,260 | $8.03M | 0.00% |
| Rice Hall James & Associates, LLC | 75,469 | $3.81M | 0.21% |
| Congress Asset Management Co | 66,641 | $3.36M | 0.02% |
| Trexquant Investment LP | 25,523 | $1.29M | 0.02% |
| SEI Investments Co | 20,823 | $1.05M | 0.00% |
| ExodusPoint Capital Management, LP | 16,855 | $850.0K | 0.01% |
| UBS Oconnor LLC | 16,000 | $806.7K | 0.02% |
| AlphaCentric Advisors LLC | 14,000 | $705.9K | 0.52% |
| HRT Financial LP | 13,592 | $685.0K | 0.00% |
| Arizona State Retirement System | 6,336 | $319.5K | 0.00% |
| Teacher Retirement System of Texas | 5,519 | $278.0K | 0.00% |
| US Bancorp | 869 | $43.8K | 0.00% |
| Clear Street Markets LLC | 90 | $5.00K | 0.00% |
| J.Safra Asset Management Corp | 8 | $395 | 0.00% |
Sold out (19)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Logos Global Management LP | 750,000 | $33.0M |
| TimesSquare Capital Management, LLC | 203,737 | $8.96M |
| Walleye Capital LLC | 86,278 | $3.79M |
| Eversept Partners, LP | 71,596 | $3.15M |
| Twinbeech Capital LP | 58,552 | $2.57M |
| Capital Fund Management S.A. | 29,243 | $1.29M |
| Susquehanna International Group, LLP | 16,964 | $745.9K |
| Jump Financial, LLC | 15,900 | $699.1K |
| CenterBook Partners LP | 15,360 | $675.4K |
| Hudson Bay Capital Management LP | 15,000 | $659.5K |
| Engineers Gate Manager LP | 12,269 | $539.5K |
| Cinctive Capital Management LP | 10,181 | $447.7K |
| Pearl River Capital, LLC | 8,067 | $354.7K |
| Connor, Clark & Lunn Investment Management Ltd. | 7,409 | $325.8K |
| Group One Trading, L.P. | 6,832 | $300.4K |
| Quarry LP | 3,000 | $131.9K |
| Belvedere Trading LLC | 2,860 | $125.8K |
| Simplex Trading, LLC | 2,118 | $93.0K |
| New York State Common Retirement Fund | 140 | $6.16K |
Not filed for Q3 2024 yet (1)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 392,024 | $17.2M |